{"brief_title": "Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)", "brief_summary": "The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.", "condition": "Metastases", "intervention_type": "Drug", "intervention_name": "Ixabepilone", "description": "Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.", "arm_group_label": "1", "other_name": "BMS-247550", "criteria": "Inclusion Criteria: - Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant - No more than 3 prior chemotherapy regimens in the metastatic setting - Must have at least one target lesion that is radiographically measurable - Good performance status - No history of or current brain or leptomeningeal disease", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00080262.xml"}